Skip to main content
Search
Main content
NPJ Genom Med
Published

Huntington's disease age at motor onset is modified by the tandem hexamer repeat in TCERG1.

Authors

Sergey V Lobanov, Branduff McAllister, Mia McDade-Kumar, G Bernhard Landwehrmeyer, Michael Orth, Anne E Rosser, , Jane S Paulsen, , Jong-Min Lee, Marcy E MacDonald, James F Gusella, Jeffrey D Long, Mina Ryten, Nigel M Williams, Peter Holmans, Thomas H Massey, Lesley Jones

Abstract

Huntington's disease is caused by an expanded CAG tract in HTT. The length of the CAG tract accounts for over half the variance in age at onset of disease, and is influenced by other genetic factors, mostly implicating the DNA maintenance machinery. We examined a single nucleotide variant, rs79727797, on chromosome 5 in the TCERG1 gene, previously reported to be associated with Huntington's disease and a quasi-tandem repeat (QTR) hexamer in exon 4 of TCERG1 with a central pure repeat. We developed a method for calling perfect and imperfect repeats from exome-sequencing data, and tested association between the QTR in TCERG1 and residual age at motor onset (after correcting for the effects of CAG length in the HTT gene) in 610 individuals with Huntington's disease via regression analysis. We found a significant association between age at onset and the sum of the repeat lengths from both alleles of the QTR (p = 2.1 × 10-9), with each added repeat hexamer reducing age at onset by one year (95% confidence interval [0.7, 1.4]). This association explained that previously observed with rs79727797. The association with age at onset in the genome-wide association study is due to a QTR hexamer in TCERG1, translated to a glutamine/alanine tract in the protein. We could not distinguish whether this was due to cis-effects of the hexamer repeat on gene expression or of the encoded glutamine/alanine tract in the protein. These results motivate further study of the mechanisms by which TCERG1 modifies onset of HD.

PMID:36064847 | DOI:10.1038/s41525-022-00317-w

UK DRI Authors

Paul Matthews

Prof Paul Matthews

Group Leader

Exploring neuronal vulnerability and genetic risk variants in Alzheimer’s progression

Prof Paul Matthews
Paul Matthews

Prof Paul Matthews

Group Leader

Exploring neuronal vulnerability and genetic risk variants in Alzheimer’s progression

Prof Paul Matthews
Mina Ryten

Prof Mina Ryten

Centre Director

Leveraging brain transcriptomics to understand the pathophysiology of Lewy body diseases

Prof Mina Ryten